fda semaglutide warning september 2025 Wegovy pill for weight loss approved by FDA; 1st of its kind July 29, 2024: FDA issued

For example, semaglutide has more extensive cardiovascular outcome data (from the SELECT trial), which may matter for patients with significant heart disease risk

it could reflect the benefits of weight loss, the direct brain effects of the medication, or a combination of both

And while that basic framework comes straight from the Phase 2 clinical trial published in the New England Journal of Medicine , it tells you almost nothing about what dose is right for you specifically

OFA also submitted a comment to the FDA that argues the semaglutide shortage remains ongoing: OFA conservatively estimates that roughly 80 million prescriptions for semaglutide were fulfilled with compounded semaglutide in the last 12 months, inclusive of 503A pharmacy compounders and 503B outsourcing facilities